Acute Allergic Reaction Management in Infants
Justification for Immediate Epinephrine
- The American Academy of Allergy, Asthma, and Immunology recommends administering epinephrine intramuscularly immediately as first-line treatment for any systemic allergic reaction, even when presenting with only urticaria and erythema, because these symptoms can rapidly progress to potentially fatal anaphylaxis within minutes 1.
- The American Academy of Pediatrics specifically warns against waiting for respiratory or cardiovascular symptoms to develop before administering epinephrine, as urticaria alone can rapidly progress to potentially fatal anaphylaxis 2.
Diagnostic Criteria
- This infant meets the Criterion 2 for anaphylaxis: two or more organ systems affected (skin/mucosa with generalized urticaria, erythema, pruritus + ocular edema) that occur rapidly after exposure to a likely allergen 3, 4.
Treatment
- For a 9-month-old infant (estimated weight 8-10 kg): administer epinephrine 0.01 mg/kg intramuscularly, equivalent to 0.08-0.10 mL of 1:1000 solution (maximum 0.15 mg) 2.
- The intramuscular route in the vastus lateralis muscle achieves maximum plasma concentrations in 8 ± 2 minutes, compared to 34 ± 14 minutes via subcutaneous route 3.
Critical Errors to Avoid
- Do not rely solely on antihistamines: they are ineffective for treating anaphylaxis and have a dangerously slow onset of action 2.
- Do not wait for respiratory (wheezing, stridor, dyspnea) or cardiovascular (hypotension, syncope) symptoms to appear before administering epinephrine, as delayed treatment is associated with fatal outcomes 2, 6.
Adjuvant Treatment after Epinephrine
- Administer diphenhydramine 1 mg/kg (maximum 25-50 mg) orally or IV for symptomatic relief of urticaria and pruritus 1, 7.
- Add ranitidine (H2 antihistamine) as adjuvant therapy for enhanced effect 1, 7.
Observation and Monitoring
- Observe the patient for a minimum of 4-6 hours after treatment, or longer depending on the severity of the reaction 1, 7.
- Monitor specifically for: progression to respiratory symptoms, development of hypotension or cardiovascular symptoms, and recurrence of cutaneous symptoms suggesting a biphasic reaction 7.